GALVESTON, TX, May 2, 2016. Chrysalis BioTherapeutics, Inc. today announced receipt of a $3 million grant from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to continue development of TP508 as a nuclear medical countermeasure. The drug is intended to be used in the event of a nuclear accident or the intentional detonation of a nuclear device to prevent radiation sickness and increase both survival and quality-of-life for those who survive.
Chrysalis BioTherapeutics has been developing TP508 as a medical countermeasure that could be quickly administered to thousands of people under emergency field conditions. In controlled preclinical studies, TP508 has significantly increased survival and delayed mortality when injected up to 24 hours after lethal radiation exposure.
"A single injection of TP508 protects endothelial cells lining blood vessels and stimulates stem cells to replace radiation-damaged cells," explained CEO of Chrysalis, Dr. Darrell Carney. "Administering TP508 after radiation exposure counteracts the effects of radiation on microvascular endothelial cells and stem cells in bone marrow, gastrointestinal crypts, skin, and even those in the brain."
Read more: http://www.eurekalert.org/pub_releases/2016-05/cbi-cbr050916.php